Treatment with obinutuzumab plus venetoclax reshapes the TRB repertoire of CLL patients
Results The TRB repertoire was characterized in 137 samples, representing 59 patients from the HOVON-139/GIVE trial at trial entry, after one year of obinutuzumab plus…
